Trial Profile
TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TAS-CC4 Study
- 05 Mar 2018 New trial record